Amphotericin B formulations: a comparative review of efficacy and toxicity

Hamill, Richard J.

doi:10.1007/s40265-013-0069-4

Cited by 807Antifungal resistance and susceptibilityFungal Infections and StudiesAntibiotics Pharmacokinetics and Efficacy

Amphotericin B formulations: a comparative review of efficacy and toxicity

Hamill, Richard J.·2013·Drugs

DOI 10.1007/s40265-013-0069-4

Open this paper in CoChat — free account

Abstract

Because of the increasing prevalence and changing microbiological spectrum of invasive fungal infections, some form of amphotericin B still provides the most reliable and broad spectrum therapeutic alternative. However, the use of amphotericin B deoxycholate is accompanied by dose-limited toxicities, most importantly, infusion-related reactions and nephrotoxicity. In an attempt to improve the therapeutic index of amphotericin B, three lipid-associated formulations were developed, including amphotericin B lipid complex (ABLC), liposomal amphotericin B (L-AmB), and amphotericin B colloidal dispersion (ABCD). The lipid composition of all three of these preparations differs considerably and contributes to substantially different pharmacokinetic parameters. ABLC is the largest of the lipid preparations. Because of its size, it is taken up rapidly by macrophages and becomes sequestered in tissues of the mononuclear phagocyte system such as the liver and spleen. Consequently, compared with the conventional formulation, it has lower circulating amphotericin B serum concentrations, reflected in a marked increase in volume of distribution and clearance. Lung levels are considerably higher than those achieved with other lipid-associated preparations. The recommended therapeutic dose of ABLC is 5 mg/kg/day. Because of its small size and negative charge, L-AmB avoids substantial recognition and uptake by the mononuclear phagocyte system. Therefore, a single dose of L-AmB results in a much higher peak plasma level (Cmax) than conventional amphotericin B deoxycholate and a much larger area under the concentration-time curve. Tissue concentrations in patients receiving L-AmB tend to be highest in the liver and spleen and much lower in kidneys and lung. Recommended therapeutic dosages are 3-6 mg/kg/day. After intravenous infusion, ABCD complexes remain largely intact and are rapidly removed from the circulation by cells of the macrophage phagocyte system. On a milligram-to-milligram basis, the Cmax achieved is lower than that attained by conventional amphotericin B, although the larger doses of ABCD that are administered produce an absolute level that is similar to amphotericin B. ABCD exhibits dose-limiting, infusion-related toxicities; consequently, the administered dosages should not exceed 3-4 mg/kg/day. The few comparative clinical trials that have been completed with the lipid-associated formulations have not demonstrated important clinical differences among these agents and amphotericin B for efficacy, although there are significant safety benefits of the lipid products. Furthermore, only one published trial has ever compared one lipid product against another for any indication. The results of these trials are particularly difficult to interpret because of major heterogeneities in study design, disease definitions, drug dosages, differences in clinical and microbiological endpoints as well as specific outcomes examined. Nevertheless, it is possible to derive some general conclusions given the available data. The most commonly studied syndrome has been empiric therapy for febrile neutropenic patients, where the lipid-associated preparations did not appear to provide a survival benefit over conventional amphotericin B deoxycholate, but did offer a significant advantage for the prevention of various breakthrough invasive fungal infections. For treatment of documented invasive fungal infections that usually involved hematological malignancy patients, no individual randomized trial has demonstrated a mortality benefit due to therapy with one of the lipid formulations. Results from meta-analyses have been contradictory, with one demonstrating a mortality benefit from all-cause mortality and one that did not demonstrate a mortality benefit. In the only published study to examine HIV-infected patients with disseminated histoplasmosis, clinical success and mortality were significantly better with L-AmB compared with amphotericin B deoxycholate; there were no differences in microbiological outcomes between treatment groups. The lipid-associated preparations were not significantly better than amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis for either clinical or microbiological outcomes that were studied. In all of the trials that specifically examined renal toxicity, the lipid-associated formulations were significantly less nephrotoxic than amphotericin B deoxycholate. Infusion-related reactions occurred less frequently with L-AmB when compared with amphotericin B deoxycholate; however, ABCD had equivalent or more frequent infusion-related reactions than conventional amphotericin B, and this resulted in the cessation of at least one clinical trial. At the present time, this particular lipid formulation is no longer commercially available. For the treatment of most invasive fungal infections, an amphotericin B lipid formulation provides a safer alternative than conventional amphotericin B, with at least equivalent efficacy. As the cost of therapy with these agents continues to decline, these drugs will likely maintain their important role in the antifungal drug armamentarium because of their efficacy and improved safety profile.

Integrity signals

Registry

Crossref · 10.1007/s40265-013-0069-4

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Amphotericin B has been widely studied and shown to induce antifungal persistence in Candida spp. biofilms and Trichosporon spp.
“Amphotericin B which belongs to polyenes class, due to its potent fungicidal activity and the rarity of resistance [35–37], has been widely studied and shown to induce antifungal persistence in Candida spp. biofilms and Trichosporon spp.”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [36]

Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant‐Associated Infection Surveillance Network (TRANSNET) Database
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456 · see citing works
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205 · see citing works
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,013 · see citing works
Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)
Cornely, O. A., Maertens, J. A., Bresnik, M., Ebrahimi, R., Ullmann, A. J., Bouza, E., Heußel, C. P., Lortholary, O., Rieger, C. T., Boehme, A., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/514341 · Cited by 745 · see citing works
A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia
Wingard, J. R., White, M. H., Anaissie, E. J., Raffalli, J. T., Goodman, J., Arrieta, A. C., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 524 · see citing works
Mortality and Costs of Acute Renal Failure Associated with Amphotericin B Therapy
Bates, D. W., Su, L., Yu, D. T., Chertow, G. M., Seger, D. L., Gomes, D. R. J., Dasbach, E. J., & Platt, R. (2001) · Clinical Infectious Diseases · doi:10.1086/319211 · Cited by 451 · see citing works
A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaløy, S., Catovsky, D., Pinkerton, R., Schey, S., Jacobs, F., Oakhill, A., et al. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2473063.x · Cited by 437 · see citing works
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Sundar, S., Chakravarty, J., Agarwal, D., Rai, M., & Murray, H. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903627 · Cited by 436 · see citing works
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404 · see citing works
Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with Aspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study
Walsh, T. J., Goodman, J. L., Pappas, P. G., Bekersky, I., Buell, D. N., Roden, M. M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401 · see citing works
Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
Wong‐Beringer, A., Jacobs, R. A., & Guglielmo, B. J. (1998) · Clinical Infectious Diseases · doi:10.1086/514704 · Cited by 398 · see citing works
Comparative Efficacy and Distribution of Lipid Formulations of Amphotericin B in Experimental Candida albicans Infection of the Central Nervous System
Groll, A. H., Giri, N., Petraitis, V., Petraitienė, R., Candelario, M., Bacher, J., Piscitelli, S. C., & Walsh, T. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315643 · Cited by 373 · see citing works
Clinical Significance of Nephrotoxicity in Patients Treated with Amphotericin B for Suspected or Proven Aspergillosis
Wingard, J. R., Kubilis, P. S., Lee, L., Yee, G. C., White, M. H., Louise, W., Bowden, R. A., Anaissie, E. J., Hiemenz, J., & LISTER, J. W. (1999) · Clinical Infectious Diseases · doi:10.1086/313498 · Cited by 368 · see citing works
Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS
Johnson, P. C., Wheat, L. J., Cloud, G. A., Goldman, M., Lancaster, D., Bamberger, D. M., Powderly, W. G., Hafner, R., Kauffman, C. A., & Dismukes, W. E. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-2-200207160-00008 · Cited by 366 · see citing works
Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis
Bern, C., Adler‐Moore, J., Berenguer, J., Boelaert, M., den Boer, M., Davidson, R. N., Figueras, C., Gradoni, L., Kafetzis, D. A., Ritmeijer, K., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/507530 · Cited by 342 · see citing works
A Double‐Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients
Bowden, R. A., Chandrasekar, P. H., White, M. H., Li, X., Pietrelli, L. A., Gurwith, M., van Burik, J., Laverdière, M., Safrin, S., & Wingard, J. R. (2002) · Clinical Infectious Diseases · doi:10.1086/341401 · Cited by 334 · see citing works
Invasive Non- Aspergillus Mold Infections in Transplant Recipients, United States, 2001–2006
Park, B. J., Pappas, P. G., Wannemuehler, K. A., Alexander, B. D., Anaissie, E. J., Andes, D. R., Baddley, J. W., Brown, J. M., Brumble, L. M., Freifeld, A. G., et al. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110087 · Cited by 321 · see citing works
Liposomal Amphotericin B
Moen, M. D., Lyseng-Williamson, K. A., & Scott, L. J. (2009) · Drugs · doi:10.2165/00003495-200969030-00010 · Cited by 319 · see citing works
Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia‐associated invasive fungal infections
Leenders, A. C. A. P., Daenen, S. M. G. J., Jansen, R. L. H., Hop, W. C. J., Löwenberg, B., Wijermans, P., Cornelissen, J. J., Herbrecht, R., van der Lelie, H., Hoogsteden, H. C., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00944.x · Cited by 317 · see citing works
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B
Walsh, T. J., MELCHER, G. P., Rinaldi, M. G., Lecciones, J., McGough, D. A., Kelly, P. M., Lee, J. K., Callender, D. P., Rubin, M., & Pizzo, P. A. (1990) · Journal of Clinical Microbiology · doi:10.1128/jcm.28.7.1616-1622.1990 · Cited by 310 · see citing works
Randomized, Double‐Blind Clinical Trial of Amphotericin B Colloidal Dispersion vs. Amphotericin B in the Empirical Treatment of Fever and Neutropenia
White, M. H., Bowden, R. A., Sandler, E. S., Graham, M. L., Noskin, G. A., Wingard, J. R., Goldman, M., van Burik, J., McCabe, A., Lin, J. S., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/514672 · Cited by 303 · see citing works
U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis
Meyerhoff, A. (1999) · Clinical Infectious Diseases · doi:10.1086/515085 · Cited by 296 · see citing works
Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species
Lackner, M., de Hoog, S., Verweij, P. E., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05910-11 · Cited by 292 · see citing works
Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
Leenders, A. C. A. P., Reiss, P., Portegies, P., Clezy, K. R., Hop, W. C. J., Hoy, J., Borleffs, J. C. C., Allworth, T., Kauffmann, R. H., Jones, P., et al. (1997) · AIDS · doi:10.1097/00002030-199712000-00010 · Cited by 287 · see citing works
Liposomal and Lipid Formulations of Amphotericin B
Janknegt, R., de Marie, S., Bakker‐Woudenberg, I. A. J. M., & Crommelin, D. J. A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223040-00004 · Cited by 272 · see citing works
Leishmaniasis impact and treatment access
den Boer, M., Argaw, D., Jannin, J. G., & Alvar, J. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03635.x · Cited by 265 · see citing works
Overview of the lipid formulations of amphotericin B
Dupont, B. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.31 · Cited by 261 · see citing works
In Vitro Amphotericin B Resistance in Clinical Isolates of Aspergillus terreus , with a Head-to-Head Comparison to Voriconazole
Sutton, D. A., Sanche, S. E., Revankar, S. G., Fothergill, A. W., & Rinaldi, M. G. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.7.2343-2345.1999 · Cited by 254 · see citing works
Development, Characterization, Efficacy and Mode of Action of Ambisome, A Unilamellar Liposomal Formulation of Amphotericin B
Adler‐Moore, J., & Proffitt, R. T. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150729 · Cited by 252 · see citing works
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
Klepser, M. E., Wolfe, E. J., Jones, R. N., Nightingale, C. H., & Pfaller, M. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1392 · Cited by 245 · see citing works
Plasma Protein Binding of Amphotericin B and Pharmacokinetics of Bound versus Unbound Amphotericin B after Administration of Intravenous Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.834-840.2002 · Cited by 237 · see citing works
AmBisome (Liposomal Amphotericin B): A Comparative Review
Boswell, G. W., Buell, D. N., & Bekersky, I. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04464.x · Cited by 227 · see citing works
The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012
Azie, N., Neofytos, D., Pfaller, M., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.06.012 · Cited by 222 · see citing works
The Antifungal Drug Amphotericin B Promotes Inflammatory Cytokine Release by a Toll-like Receptor- and CD14-dependent Mechanism
Sau, K., Mambula, S. S., Latz, E., Henneke, P., Golenbock, D. T., & Levitz, S. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306137200 · Cited by 216 · see citing works
Amphotericin B nephrotoxicity
Sawaya, B. P., Briggs, J. P., & Schnermann, J. B. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v62154 · Cited by 203 · see citing works
Amphotericin B Lipid Complex Compared with Amphotericin B in the Treatment of Cryptococcal Meningitis in Patients with AIDS
Sharkey, P. K., Graybill, J. R., Johnson, E. S., et al. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.315 · Cited by 199 · see citing works
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations
Barrett, J. P., Vardulaki, K., Conlon, C. P., Cooke, J., Daza-Ramirez, P., Evans, E. G. V., Hawkey, P. M., Herbrecht, R., Marks, D. I., Moraleda, J. M., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80125-x · Cited by 190 · see citing works
Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis
Girois, S. B., Chapuis, F. R., Decullier, É., & Revol, B. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0080-0 · Cited by 173 · see citing works
Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDS‐Associated Acute Cryptococcal Meningitis: A Randomized, Double‐Blind Clinical Trial of Efficacy and Safety
Hamill, R. J., Sobel, J. D., El-Sadr, W. M., Johnson, P. C., Graybill, J. R., Javaly, K., & Barker, D. E. (2010) · Clinical Infectious Diseases · doi:10.1086/653606 · Cited by 173 · see citing works
Self-citation
Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
White, M. H., Anaissie, E. J., Kusne, S., Wingard, J. R., Hiemenz, J., Cantor, A. B., Gurwith, M., Mond, C. D., Mamelok, R. D., & Bowden, R. A. (1997) · PubMed · Cited by 166 · see citing works
Update on the Genus Trichosporon
Chagas-Neto, T. C., Chaves, G. M., & Colombo, A. L. (2008) · Mycopathologia · doi:10.1007/s11046-008-9136-x · Cited by 163 · see citing works
Bloodstream Infections Due to Trichosporon spp.: Species Distribution, Trichosporon asahii Genotypes Determined on the Basis of Ribosomal DNA Intergenic Spacer 1 Sequencing, and Antifungal Susceptibility Testing
Chagas-Neto, T. C., Chaves, G. M., Melo, A. S. D. A., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01614-08 · Cited by 162 · see citing works
Immunocompromised Hosts: Immunopharmacology of Modern Antifungals
Ben‐Ami, R., Lewis, R. E., & Kontoyiannis, D. P. (2008) · Clinical Infectious Diseases · doi:10.1086/589290 · Cited by 140 · see citing works
Lipid-based amphotericin B: a review of the last 10 years of use
Hann, I. M., & Prentice, H. G. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00341-1 · Cited by 135 · see citing works
Comparison of Amphotericin B Lipid Complex (ABLC) vs. AmBisome in the Treatment of Suspected or Documented Fungal Infections in Patients with Leukemia
Fleming, R. V., Kantarjian, H. M., Husni, R., Rolston, K. V. I., Lim, J. T., RAAD, I. I., Pierce, S. A., Cortes, J. E., & Estey, E. H. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109097650 · Cited by 134 · see citing works
Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits
Lee, J. W., Amantea, M., Francis, P. A., Navarro, E. E., Bacher, J. D., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.713 · Cited by 134 · see citing works
In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains
Pujol, I., Guarro, J., Gené, J., et al. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/39.2.163 · Cited by 130 · see citing works
Amphotericin B lipid preparations: what are the differences?
Adler‐Moore, J., & Proffitt, R. T. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01979.x · Cited by 128 · see citing works
3 Biological Activity of Polyene Antibiotics
HAMMOND, S. M. (1977) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70148-6 · Cited by 126 · see citing works
Pretreatment Regimens for Adverse Events Related to Infusion of Amphotericin B
Goodwin, S., Cleary, J. D., Walawander, C. A., et al. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.4.755 · Cited by 122 · see citing works
Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4
Bellocchio, S., Gaziano, R., Bozza, S., Rossi, G., Montagnoli, C., Perruccio, K., Calvitti, M., Pitzurra, L., & Romani, L. R. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh542 · Cited by 118 · see citing works
Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion
Vogelsinger, H. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl141 · Cited by 118 · see citing works
Phase I Study of Amphotericin B Colloidal Dispersion for the Treatment of Invasive Fungal Infections after Marrow Transplant
Bowden, R. A., Cays, M., Gooley, T. A., Mamelok, R. D., & van Burik, J. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.5.1208 · Cited by 117 · see citing works
Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols
Readio, J. D., & Bittman, R. (1982) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(82)90103-1 · Cited by 115 · see citing works
Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs
Guo, L. S. S., Fielding, R. M., Lasiç, D. D., Hamilton, R. L., & Mufson, D. (1991) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(91)90249-n · Cited by 110 · see citing works
Infusion‐related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels
Arning, M., Kliche, K. O., Heer‐Sonderhoff, A. H., & Wehmeier, A. (1995) · Mycoses · doi:10.1111/j.1439-0507.1995.tb00020.x · Cited by 110 · see citing works
Drug-Induced Nephrotoxicity Caused by Amphotericin B Lipid Complex and Liposomal Amphotericin B
Safdar, A., Ma, J., Saliba, F., Dupont, B., Wingard, J. R., Hachem, R. Y., Mattiuzzi, G. N., Chandrasekar, P. H., Kontoyiannis, D. P., Rolston, K. V. I., et al. (2010) · Medicine · doi:10.1097/md.0b013e3181e9441b · Cited by 108 · see citing works
Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies
Adedoyin, A. B., Bernardo, J. F., Swenson, C. E., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2201 · Cited by 92 · see citing works
The lipid formulations of amphotericin B
Herbrecht, R., Natarajan‐Amé, S., Nivoix, Y., et al. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.8.1277 · Cited by 91 · see citing works
High-Frequency, In Vitro Reversible Switching of Candida lusitaniae Clinical Isolates from Amphotericin B Susceptibility to Resistance
Yoon, S. A., Vázquez, J. A., Steffan, P. E., Sobel, J. D., & Akins, R. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.836 · Cited by 90 · see citing works
Clinical and Economic Outcomes of Conventional Amphotericin B–Associated Nephrotoxicity
Harbarth, S., Burke, J. P., Lloyd, J. F., Evans, R. S., Pestotnik, S. L., & Samore, M. H. (2002) · Clinical Infectious Diseases · doi:10.1086/344468 · Cited by 86 · see citing works
Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B
Wasan, K. M., Rosenblum, M. G., Cheung, L. H., et al. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.2.223 · Cited by 84 · see citing works
Low‐dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial
Subirá, M., Martino, R., Gómez, L., Martí, J. M., Estany, C., & Sierra, J. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00239.x · Cited by 82 · see citing works
In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important
Swenson, C. E., Perkins, W. R., Roberts, P., Ahmad, I., Stevens, R., Stevens, D. A., & Janoff, A. S. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.767 · Cited by 82 · see citing works
Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia
Johansen, H. K., & Gøtzsche, P. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000969.pub2 · Cited by 77 · see citing works
Amphotericin B Activation of Human Genes Encoding for Cytokines
Rogers, P. D., Jenkins, J. K., Chapman, S. W., et al. (1998) · The Journal of Infectious Diseases · doi:10.1086/314495 · Cited by 71 · see citing works
Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial
Timmers, G. J., Zweegman, S., Simoons‐Smit, A. M., et al. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702243 · Cited by 68 · see citing works
Supramolecular lipidic drug delivery systems: From laboratory to clinic A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B
Hillery, A. M. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00496-6 · Cited by 66 · see citing works
Differential Expression of Cytokines and Chemokines in Human Monocytes Induced by Lipid Formulations of Amphotericin B
Simitsopoulou, M., Roilides, E., Dotis, J., Dalakiouridou, M., Dudkova, F., Andreadou, E., & Walsh, T. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1397-1403.2005 · Cited by 66 · see citing works
Increasing Prevalence of Ampicillin- Resistant, Non-Beta-Lactamase-Producing Strains of Haemophilus influenzae in Children in Japan
Seki, H., Kasahara, Y., Ohta, K., et al. (1999) · Chemotherapy · doi:10.1159/000007160 · Cited by 60 · see citing works
Safety and Efficacy of Amphotericin B Colloidal Dispersion
Herbrecht, R., Letscher, V., Andrès, E., et al. (1999) · Chemotherapy · doi:10.1159/000048472 · Cited by 51 · see citing works
Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone
Louie, A., Baltch, A. L., Franke, M. A., Smith, R. P., & Gordon, M. A. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.6.975 · Cited by 48 · see citing works
Lipid‐Based Amphotericin B for the Treatment of Fungal Infections
Slain, D. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.4.306.30934 · Cited by 46 · see citing works
Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature
Martino, R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003179 · Cited by 45 · see citing works
Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia
Johansen, H. K., & Gøtzsche, P. C. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000969 · Cited by 43 · see citing works
Selective Toxicity and Enhanced Therapeutic Index of Liposomal Polyene Antibiotics in Systemic Fungal Infections
Juliano, R. L., Lopez‐Berestein, G., Hopfer, R. L., et al. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb18416.x · Cited by 41 · see citing works
Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?
Mehta, J. (1997) · Leukemia Research · doi:10.1016/s0145-2126(96)00075-6 · Cited by 37 · see citing works
Characteristics of Lipid-Based Formulations That Influence Their Biological Behavior in the Plasma of Patients
Wasan, K. M., & Lopez‐Berestein, G. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.5.1126 · Cited by 36 · see citing works
Diversity of lipid-based polyene formulations and their behavior in biological systems
Wasan, K. M., & Lopez‐Berestein, G. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01575125 · Cited by 32 · see citing works
Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens
Hope, W. W., Goodwin, J., Felton, T., Ellis, M. E., & Stevens, D. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00933-12 · Cited by 32 · see citing works
Variability in Polyene Content and Cellular Toxicity Among Deoxycholate Amphotericin B Formulations
Cleary, J. D., Rogers, P. D., & Chapman, S. W. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.5.572.32209 · Cited by 28 · see citing works
The use of amphotericin B to detect inhibitors of cellular cholesterol biosynthesis
Krieger, M. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90700-5 · Cited by 24 · see citing works
Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis
Gavaldà, J., Martín-Gómez, M. T., López, P., et al. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01262.x · Cited by 23 · see citing works
Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content
Kennedy, A. L., & Wasan, K. M. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js990101z · Cited by 21 · see citing works
Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis
Martín-Gómez, M. T. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh003 · Cited by 19 · see citing works
Amphotericin B Colloidal Dispersion
Working, P. K. (1999) · Chemotherapy · doi:10.1159/000048466 · Cited by 14 · see citing works
Fungal Phospholipase Activity and Susceptibility to Lipid Preparations of Amphotericin B
Gottfreðsson, M., Jessup, C. J., Cox, G. M., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3231-3233.2001 · Cited by 8 · see citing works

Flagged first, then by citations

Sorted by citations

Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400 · see citing works
The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866 · see citing works
Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Roemer, T., & Krysan, D. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019703 · Cited by 593 · see citing works
Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537 · see citing works
Molecular Evolution of Antifungal Drug Resistance
Robbins, N., Caplan, T., & Cowen, L. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-030117-020345 · Cited by 441 · see citing works
Antifungal Agents
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351 · see citing works
Candida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327 · see citing works
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271 · see citing works
Aspiring Antifungals: Review of Current Antifungal Pipeline Developments
Gintjee, T., Donnelley, M., & Thompson, G. (2020) · Journal of Fungi · doi:10.3390/jof6010028 · Cited by 225 · see citing works
Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117 · see citing works
Synergistic effects of tea catechin epigallocatechin gallate and antimycotics against oral Candida species
Ning, Y., Ling, J., & Wu, C. D. (2015) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2015.07.001 · Cited by 56 · see citing works
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35 · see citing works
Quantitative analysis of cholesterol oxidation products and desmosterol in parenteral liposomal pharmaceutical formulations
Wang, C., Siriwardane, D. A., Jiang, W., & Mudalige, T. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118576 · Cited by 24 · see citing works
In Vitro and In Vivo Study of Amphotericin B Formulation with Quaternized Bioreducible Lipidoids
Liu, F., Yang, L., Li, Y., Junier, A., Ma, F., Chen, J., Han, H., Glass, Z., Zhao, X., Kumamoto, C. A., et al. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01722 · Cited by 21 · see citing works
Antifungal persistence: Clinical relevance and mechanisms
Wang, R., Lv, J., Chen, L., Zhao, Y., & Du, H. (2025) · PLoS pathogens · doi:10.1371/journal.ppat.1013456 · Cited by 12 · see citing works

What is the current and future status of conventional amphotericin B?
Kleinberg, M. E. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.03.013 · Cited by 148 · see citing works
Amphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid Formulations
Sundar, S., Mehta, H., Suresh, A. V., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380971 · Cited by 189 · see citing works
Calcium-channel blocking agents as therapy for amphotericin B nephrotoxicity
Brouhard, B. H., & Baetz-Greenwalt, B. (1992) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.59.3.263 · Cited by 5 · see citing works
Relapse of kala-azar after use of multiple drugs: A case report and brief review of literature
Pandey, K., Pun, S., & Pandey, B. (2012) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.96703 · Cited by 10 · see citing works
Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment
Falci, D. R., dos Santos, R. P., Wirth, F., et al. (2009) · Mycoses · doi:10.1111/j.1439-0507.2009.01805.x · Cited by 18 · see citing works

Authors: Hamill, R. J.
Affiliations: Michael E. DeBakey VA Medical Center (US)
Corresponding author: Hamill, Richard J.
ORCID: Hamill, Richard J.
Venue: Drugs
Publisher: Springer Science and Business Media LLC
Published: 2013-06
Volume: 73
Issue: 9
Pages: 919-934
ISSN: 0012-6667 (ISSN-L)
1179-1950
DOI: 10.1007/s40265-013-0069-4
OpenAlex: W1991149656
Cited by: 807
References: 87
Citations by year: 2026: 71 · 2025: 69 · 2024: 94 · 2023: 69 · 2022: 90 · 2021: 79 · 2020: 80 · 2019: 50 · 2018: 54 · 2017: 52 · 2016: 36 · 2015: 25 · 2014: 30 · 2013: 5
FWCI: 4.15
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Drugs (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Department of Veterans Affairs
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
Keywords: amphotericin B, amphotericin B lipid complex, liposomal amphotericin B, amphotericin B colloidal dispersion, amphotericin B deoxycholate, invasive fungal infections, pharmacokinetics, nephrotoxicity, infusion reactions, reticuloendothelial system, therapeutic index, antifungal agents
MeSH terms: Amphotericin B, Animals, Antifungal Agents, Chemistry, Pharmaceutical, Fungi, Humans, Lipids, Mycoses

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amphotericin B formulations: a comparative review of efficacy and toxicity

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks